Robert S. Breuil net worth and biography

Robert Breuil Biography and Net Worth

CFO of Graybug Vision

Robert has over 20 years of experience in the biopharmaceutical and drug delivery industries, serving exclusively as Chief Financial Officer (CFO) since 2003. Prior to joining Graybug Vision, he was the CFO of Corium, Inc., a commercial-stage biopharmaceutical company, for seven years, taking the company from private to public and then through the sale to a private equity buyer. Prior to that, he was the CFO of Codexis, Inc., a developer of biocatalysts for the pharmaceutical and fine chemical production industries for three and a half years. In 2002, he became the CFO of Aerogen, Inc., a specialty pharmaceutical company focusing on the field of aerosolized drug delivery, which was acquired by Nektar Therapeutics in 2005. Prior to Aerogen, Robert worked at ALZA Corporation, where he held numerous positions including Director of Corporate Planning, Analysis and Controller. In 2001, ALZA was acquired by Johnson & Johnson and Robert stayed on as Controller until joining Aerogen in 2002. Before his industry experience, he served for eight years as a naval officer and aviator. Robert holds a B.S.E.E. from the United States Naval Academy and an M.B.A. from the Stanford Graduate School of Business.

What is Robert S. Breuil's net worth?: The estimated net worth of Robert S. Breuil is at least $4,940.42 as of March 31st, 2022. Mr. Breuil owns 1,466 shares of Graybug Vision stock worth more than $4,940 as of November 15th. This net worth estimate does not reflect any other investments that Mr. Breuil may own. Additionally, Mr. Breuil receives an annual salary of $577,470.00 as CFO at Graybug Vision. Learn More about Robert S. Breuil's net worth.
How old is Robert S. Breuil?: Mr. Breuil is currently 60 years old. There are 4 older executives and no younger executives at Graybug Vision. The oldest executive at Graybug Vision is Dr. Gerald D. Cagle Ph.D., Sr. Advisor & Head of Bus. Devel., who is 78 years old. Learn More on Robert S. Breuil's age.
What is Robert S. Breuil's salary?: As the CFO of Graybug Vision, Inc., Mr. Breuil earns $577,470.00 per year. There are 2 executives that earn more than Mr. Breuil. The highest earning executive at Graybug Vision is Dr. Frederic Guerard Pharm.D., Pres, CEO, Sec. & Director, who commands a salary of $931,020.00 per year. Learn More on Robert S. Breuil's salary.
How do I contact Robert S. Breuil?: The corporate mailing address for Mr. Breuil and other Graybug Vision executives is , , . Graybug Vision can also be reached via email at [email protected]. Learn More on Robert S. Breuil's contact information.
Has Robert S. Breuil been buying or selling shares of Graybug Vision?: Robert S. Breuil has not been actively trading shares of Graybug Vision over the course of the past ninety days. Most recently, Robert S. Breuil sold 156 shares of the business's stock in a transaction on Thursday, March 31st. The shares were sold at an average price of $17.50, for a transaction totalling $2,730.00. Following the completion of the sale, the chief financial officer now directly owns 1,466 shares of the company's stock, valued at $25,655. Learn More on Robert S. Breuil's trading history.

Robert S. Breuil Insider Trading History at Graybug Vision

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
3/31/2022	Sell	156	$17.50	$2,730.00	1,466
9/22/2021	Sell	520	$49.70	$25,844.00

Robert S. Breuil Buying and Selling Activity at Graybug Vision

Graybug Vision Company Overview

Graybug Vision, Inc., a clinical-stage biopharmaceutical company, focuses on the development of medicines for the treatment of diseases of the retina and optic nerve. The company's lead product candidate is GB-102, an intravitreal injection of a microparticle depot formulation of sunitinib that is in Phase I/IIa and IIb clinical trials for the treatment of wet age-related macular degeneration, as well as in Phase IIa clinical trial to treat diabetic macular edema. It also develops GB-102, for the treatment of diabetic retinopathy; and GB-401, an intravitreally injected implant formulation of a beta-adrenergic receptor inhibitor to treat primary open-angle glaucoma. The company was formerly known as Graybug LLC and changed its name to Graybug Vision, Inc. in 2016. Graybug Vision, Inc. was incorporated in 2011 and is based in Redwood City, California.

Today's Range

Now: $3.37

$3.35

$3.45

50 Day Range

MA: $4.14

$3.40

$5.30

2 Week Range

Now: $3.37

$5.00

$22.12

Volume

32,908 shs

Average Volume

2,165 shs

Market Capitalization

$5.29 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.2

Election warning coming true…

From Porter & Company | Ad

If you missed it, my emergency election broadcast is now available - watch it before it's too late.

Click here to watch it now.